In-Person “Multidisciplinary Forum on Liver Cancer”
Objective:
To improve clinical decision-making in liver cancer by integrating evidence, multidisciplinary expertise, and consensus applied to complex clinical scenarios.
Specific objectives:
To analyze real-world cases of HCC and intrahepatic CCA; update diagnostic and therapeutic criteria; discuss alternatives in borderline cases; integrate a multidisciplinary and patient-centered approach; and establish regional consensus criteria that promote consistent and equitable care.
Date:
Thursday, October 22, 2026.
Location:
Auditorium of the University Healthcare Complex of Salamanca and the International Spanish Language Center.
Program:
| SCIENTIFIC LECTURE SERIES — TRANSLATIONAL SCIENCE
|
|||
| 22/10/26 | 9:20 a.m. |
OPENING LECTURE: “Translational Research in Liver Cancer: Salamanca, a Hub of Innovation” |
Prof. José Juan García Marín, Full Professor · Department of Physiology and Pharmacology · USAL · Head of the HEVEFHARM Group, CIBEREHD. |
| 22/10/26 | 9:50 a.m. | “Moving Forward Together in Cholangiocarcinoma: The Value of Collaborative Networks” | Prof. Rocío I. R. Macías
Professor · Department of Physiology and Pharmacology · USAL · Coordinator of the COST Precision-BTC Network. |
| 10/22/26 | 10:15 a.m. | “Immunotherapy and New Therapeutic Strategies for Liver Cancer” | Dr. Pedro Berraondo
Principal Investigator · Cytokine-Based Therapies Group · CIMA · University of Navarra Clinic. |
| 10/22/26 | 10:40 | OPEN DISCUSSION WITH THE AUDIENCE (15 min) | |
| 11:00
Coffee break
|
|||
| COMMUNITY — MEETING WITH PATIENTS AND FAMILIES · 11:30 a.m.–2:00 p.m.
|
|||
| 22/10/26 | 11:30 a.m. | SESSION A · 30 min — PRESENTATION BY ORGANIZATIONS
PETHCyL Association — People with Liver Disease and Liver Transplant Recipients in CYL. Magdalena Alejo. · ATUVIBI Association — Biliary Tract Diseases and Tumors. President: Elisabeth Baucells.
· Work, mission, support, and healthcare dialogue in the Community of Castile and León and at the national level
|
|
| 22/10/26 | 12:00 | BLOCK B · 60 min — MULTIDISCIPLINARY OPEN DIALOGUE
: Improving Clinical Care and Communication: AEEH Care Guidelines for Liver Disease
|
Inmaculada Sánchez, Nursing. Gastroenterology Department. Pilar Carreto, Psychologist, AECC-Salamanca.
· Lessons in Nutrition · Elena Delgado and Natalia Ramos, Nurse and Nutritionist. Endocrinology Department |
| 22/10/26 | 13:00 | BLOCK C · 60 min — THE PATIENT’S PERSPECTIVE ON HCC, CCA, AND TRANSPLANTATION
The journey from diagnosis to treatment decision. · Shared decision-making with the medical team. · The transplant experience: waiting, the process, and life after transplant · Unmet needs and their impact on life plans. |
A group discussion took place among all attendees, facilitated by the nursing staff and physicians
|
| 3:30 p.m.
MEETING PLACE: WELCOME COCKTAILS AND COFFEE · CIE-USAL |
|||
|
16:30-20:45 PLENARY SESSION Border Scenarios · Complex Decisions · Consensus and Networking Moderators: Dr. J. González · Dr. A. Matilla · Dr. C. Esteban · Dr. A. López Live Vote: Surgery/Transplant, Locoregional, Systemic, Uncertain/Alternative Guest panelists from Radiodiagnostics · Hepatology · Oncology · Surgery · Interventional Radiology · Nuclear Medicine |
|||
| 22/10/26 | 16:30 | SCENARIO 1 — HCC OUTSIDE THE “UP-TO-7” CRITERIA
Neoadjuvant therapy and decision on surgery/transplant · Downstaging: dual IO vs. IO + anti-VEGF · Dynamic selection · Transplant vs. resection after response
|
|
| 22/10/26 | 17:30 | SCENARIO 2 — INTERMEDIATE HCC: TACE vs. TARE vs. Early Systemic Therapy
· TACE—not eligible or TACE-refractory · Window for dual IO vs. IO + anti-VEGF · Conversion to curative therapy 6:30 PM (60 min) 🔷 SCENARIO |
|
| 10/22/26 | 6:30 p.m. | SCENARIO 3 — ADVANCED HCC WITH RESPONSE: Conversion, Adjuvant Therapy, and Surgical Rescue
· Conversion therapies: dual IO vs. IO + anti-VEGF · Post-response surgery · TALENT model · Post-resection adjuvant therapy |
|
| 10/26/22 | 7:30 p.m. | SCENARIO 4 — BORDERLINE CHOLANGIOCARCINOMA Endoscopic evaluation · Combined strategy · Surgical rescue
· TOPAZ-1: durvalumab + QT as standard · TARE in intrahepatic cholangiocarcinoma · Conversion to resection or transplantation |
|
| INTEGRATIVE CLOSING SESSION — CONSENSUS · 8:30 p.m. · 15 min
Summary of decisions by scenario · Proposal for a liver cancer network. |
|||
Seats:
75 positions for IBSAL staff
Enrollment:
Note: HUS staff who are not affiliated with IBSAL must register through the GESTION@FC training application: www.salud.jcyl.es/gestio@fc
The registration deadline is Tuesday, October 20, 2026; you can register individually through our website.
In order to successfully complete the course and receive the relevant certificate, it is necessary to complete 80% of the total program.
Please note that you can only be considered registered for the course when you receive the confirmation email, as there is a limit to the number of places available.
SELECTION METHOD:
Enrollment in the course will be carried out in strict order of enrollment (in courses with high demand, preference will be given to IBSAL personnel), according to the agreement of the IBSAL Training Commission.